CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
Patents” means all Patents within the Joint Program IP.
means the actual knowledge after performing a diligent investigation with respect to such facts and information of Chief Executive
Officer or Chief Scientific Officer of a Party or any personnel holding positions equivalent to such job titles.
Compounds” means [*****].
Party” means (i) with respect to the licenses granted in Section 2.1,
Lilly and (ii) with respect to the license granted in the proviso to Section 12.4.1(ii),
Product” means any pharmaceutical product that is comprised of or contains [*****].
Compound” means [*****].
Development Costs” means, with respect to a Licensed Compound or Licensed Product, [*****].
Grantback Know-How” means, as used in connection with any grant back license provided in Article 12, all [*****].
Grantback Patent Rights” means, as used in connection with any grant back license provided in Article 12, all Patents
Know-How” means all [*****].
Patents” means all of the Patents [*****].
Pharmaceutical Company” means a company that, together with its Affiliates, on a worldwide basis, [*****].
and “Manufacturing” means with respect to any compound or product, all activities related to the production,
manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of such compound or product or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial
manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.